Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.60 |
| ▸ | NOS1 | P29475 | 4/20 | 0.59 |
| ▸ | AXL | P30530 | 2/20 | 0.59 |
| ▸ | METAP2 | P50579 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31190582 | 0.86 | IDO1 (0.55) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL12315709 | 0.83 | METAP2 (0.64) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL28633087 | 0.78 | NOS1 (0.59) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL24460610 | 0.77 | IDO1 (0.46) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL12601112 | 0.76 | NOS1 (0.61) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL476854 | 0.74 | NOS1 (1.00) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL4314318 | 0.74 | NOS1 (1.00) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL18193497 | 0.74 | NOS1 (0.59) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL277054 | 0.74 | NOS1 (0.59) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL277055 | 0.74 | NOS1 (0.59) | IDO1NOS1AXLMETAP2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111788183-B | Heterocyclic fused phenyl compounds useful for inhibiting TNIK and medical uses thereof | 韩国化学硏究院 | 2024-02-23 | — | — | CN | claimed |
| EP-3749647-B1 | N-(5-(PHENYL)-1H-PYRAZOL-3-YL)-1H-INDOL-5-AMINE DERIVATIVES AS TNIK INHIBITORS FOR THE TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-09-27 | — | — | EP | claimed |
| US-11447469-B2 | Hetero ring-fused phenyl compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-09-20 | — | — | US | claimed |
| US-20210047300-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-02-18 | — | — | US | claimed |
| EP-3749647-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2020-12-16 | — | — | EP | claimed |
| CN-111788183-A | Heterocyclic fused phenyl compounds for inhibiting TNIK and medical uses thereof | 韩国化学硏究院 | 2020-10-16 | — | — | CN | claimed |
| WO-2019156438-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2019-08-15 | — | — | WO | claimed |
| US-9169209-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2015-10-27 | — | — | US | claimed |
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2014-09-18 | — | — | US | claimed |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| CN-120025297-A | Mycobacterium membrane protein MmpL inhibitor, pharmaceutical composition and application thereof | 和径医药科技（上海）有限公司 | 2025-05-23 | — | — | CN | disclosed |
| WO-2024220747-A2 | FLUORINATED CYCLIC DERIVATIVES OF SULFONAMIDES AND SULFONES, AND COMPOSITIONS AND METHODS THEREOF | Lysoway Therapeutics, Inc. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024137671-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | EXELIXIS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024112853-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | EXELIXIS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| EP-1740549-A2 | NOVEL IMIDAZOLES | Warner-Lambert Company LLC (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1706386-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005105079-A2 | NOVEL IMIDAZOLES | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005066136-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | PPARD, PPARA, PPARG | IDO1 3337/4885NOS1 2626/4885AXL 1495/4885 |
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NAPRT | IDO1 1238/4885NOS1 1895/4885AXL 3259/4885 |
| US-20210047300-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | TNNI3K, TNK1, TNIK | IDO1 3150/4885NOS1 1976/4885AXL 4473/4885 |
| US-11447469-B2 | Hetero ring-fused phenyl compounds for inhibiting TNIK and medical uses thereof | TNNI3K, TNK1, TNIK | IDO1 3150/4885NOS1 1976/4885AXL 4473/4885 |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | IDO1 2029/4885NOS1 498/4885AXL 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.